Anti-idiotype antibodies (anti-Id Abs) are antibodies to idiotopes that are located in the variable region, including the antigen binding site, of another antibody. When the last is the case, these anti-Id Abs can act as surrogates of the original antigen. The capability of anti-Id Abs to modulate the immune response has been the basis for the development of anti-Id vaccines against different antigens, including tumor-associated antigens. Over the years, its use in cancer has been demonstrated as effective and promising.Fil: Alonso, Daniel Fernando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Vázquez, Ana María. No especifíca;Fil: Alonso, Daniel Fernando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Macías, Amparo. No especifíca

Alonso, Daniel Fernando

Macías, Amparo

Vázquez, Ana María

Frontiers in Oncology

PubMed

CONICET Digital

EDITORIALpublished: 26 February 2013doi: 10.3389/fonc.2013.00037Anti-idiotype antibodies in cancer treatmentDaniel E. Gomez1 , Ana M. Vázquez2, Daniel F. Alonso1 and Amparo Macías21 Department of Science and Technology, Universidad Nacional de Quilmes, Buenos Aires, Argentina2 Centro de Inmunologia Molecular, La Havana, Cuba*Correspondence: degomez@unq.edu.arEdited by:Wolf Hervé Fridman, INSERM, University Paris Descartes, FranceAnti-idiotype antibodies (anti-Id Abs) are antibodies to idiotopesthat are located in the variable region, including the antigen bind-ing site, of another antibody. When the last is the case, theseanti-Id Abs can act as surrogates of the original antigen. Thecapability of anti-Id Abs to modulate the immune response hasbeen the basis for the development of anti-Id vaccines againstdifferent antigens, including tumor-associated antigens. Over theyears, its use in cancer has been demonstrated as effective andpromising. This book “Anti-idiotype antibodies in cancer treat-ment” resumes the latest findings in the field. The book startswith an opinion article by Gomez et al. (2012), whereas theauthors discuss amethod for prioritization of cancer antigens thatpaves the way to take more rational, informed decisions in vac-cine development. Following, we will find a number of reviewsthat conform a complete updating on the subject. The first oneby Kieber-Emmons et al. (2012) explore the concept of anti-IdAbs with its achievements and drawbacks. Following, Ladjemi(2012) focuses on recent achievements of use of anti-Id Abs ascancer vaccines in solid tumors. López-Requena et al. (2012)focus on the role of anti-Id vaccination in cancer managementand on the current developments used to foster anti-idiotypicB and T cell responses. Vázquez et al. (2012a,b) deeply analyzethe immunological mechanisms involved in the use of these anti-bodies, while Vázquez et al. (2012a,b) focus on racotumomab,an anti-Id vaccine already in Phase III clinical trials. Finally,Fredriksen et al. (2012) present a hypothetical model for howthe APC-targeted vaccine molecules enhance Id-specific T and Bcells. Next, the original article of Segatori et al. (2012) conveyspreclinical research on racotumomab with or without chemother-apy, and explores the biological role of N-glycolyl gangiosides ina lung cancer mouse model. Two interesting clinical case studiesare also part of this book. First, Llanos et al. (2012) report a main-tenance treatment with chemotherapy and immunotherapy in apatient with non-small cell lung cancer. Also, Sampor et al. (2012)present results about the immune response to racotumomab in achild with relapsed neuroblastoma. The book closes with a veryinteresting article by Gómez and Ardigo (2012), analyzing thepharmaceutical perspective of the development of anti-Id Abs incancer treatment, with a fresh point of view about the relationshipbetween academy and industry. We as editors were very happy towork with such an excellent group of authors, putting together abook with good quality articles that shed light to the use of anti-Id Abs in cancer. Likewise, we hope it constitutes to the readerinteresting material for their fields.REFERENCESFredriksen, A. B., Sandlie, I., andBogen, B. (2012). Targeted DNAvaccines for enhanced inductionof idiotype-specific B and T cells.Front. Oncol. 2:154. doi: 10.3389/fonc.2012.00154Gomez, D. E., Vázquez, A. M., andAlonso, D. F. (2012). Cancer antigenprioritization: a road map to workin defining vaccines against spe-cific targets. A point of view. Front.Oncol. 2:66. doi: 10.3389/fonc.2012.00066Gómez, R. E., and Ardigo, M. L. (2012).Anti-idiotype antibodies in can-cer treatment: the pharmaceuticalindustry perspective. Front. Oncol.2:147. doi: 10.3389/fonc.2012.00147Kieber-Emmons, T., Monzavi-Karbassi,B., Pashov, A., Saha, S., Murali,R., and Kohler, H. (2012). Thepromise of the anti-idiotype con-cept. Front. Oncol. 2:196. doi: 10.3389/fonc.2012.00196Ladjemi, M. Z. (2012). Anti-idiotypicantibodies as cancer vaccines:achievements and future improve-ments. Front. Oncol. 2:158. doi: 10.3389/fonc.2012.00158Llanos, A., Savignano, M., and Cinat,G. (2012). Maintenance treat-ment with chemotherapy andimmunotherapy in non-small celllung cancer: a case report. Front.Oncol. 2:152. doi: 10.3389/fonc.2012.00152López-Requena, A., Burrone, O. R.,and Cesco-Gaspere, M. (2012).Idiotypes as immunogens: facingthe challenge of inducing strongtherapeutic immune responsesagainst the variable region ofimmunoglobulins. Front. Oncol.2:159. doi: 10.3389/fonc.2012.00159Sampor, C., Guthmann, M. D.,Scursoni, A., Cacciavillano, W.,Torbidoni, A., Galluzzo, L., et al.(2012). Immune response to raco-tumomab in a child with relapsedneuroblastoma. Front. Oncol. 2:195.doi: 10.3389/fonc.2012.00195Segatori, V. I., Vazquez, A. M., Gomez,D. E., Gabri, M. R., and Alonso,D. F. (2012). Preclinical evaluationof racotumomab, an anti-idiotypemonoclonal antibody to N-glycolyl-containing gangliosides, with orwithout chemotherapy in a mousemodel of non-small cell lung cancer.Front. Oncol. 2:160. doi: 10.3389/fonc.2012.00160Vázquez, A. M., Hernández, A.M., Macías, A., Montero, E.,Gómez, D. E., Alonso, D. F.,et al. (2012a). Racotumomab: ananti-idiotype vaccine related toN-glycolyl-containing gangliosides– preclinical and clinical data. Front.Oncol. 2:150. doi: 10.3389/fonc.2012.00150Vázquez, A. M. H., Rodríguez-Zhurbenko, N., and López, A.M. V. (2012b). Anti-gangliosideanti-idiotypic vaccination: morethan molecular mimicry. Front.Oncol. 2:170. doi: 10.3389/fonc.2012.00170Received: 01 February 2013; accepted:11 February 2013; published online: 26February 2013.Citation: Gomez DE, Vázquez AM,Alonso DF and Macías A (2013) Anti-idiotype antibodies in cancer treatment.Front. Oncol. 3:37. doi: 10.3389/fonc.2013.00037This article was submitted to Frontiers inTumor Immunity, a specialty of Frontiersin Oncology.Copyright © 2013 Gomez, Vázquez,Alonso and Macías. This is an open-access article distributed under the termsof the Creative Commons AttributionLicense, which permits use, distributionand reproduction in other forums, pro-vided the original authors and sourceare credited and subject to any copy-right notices concerning any third-partygraphics etc.www.frontiersin.org February 2013 | Volume 3 | Article 37 | 1*

Anti-idiotype antibodies in cancer treatment

Daniel E. Gomez

Daniel F Alonso

Ana María eVázquez

Amparo eMacías

Directory of Open Access Journals

Editorial. Anti-idiotype antibodies in cancer treatment.

Ana M. Vázquez

Daniel F. Alonso

Amparo Macías

Frontiers - Publisher Connector

EDITORIAL
published: 26 February 2013
doi: 10.3389/fonc.2013.00037
Anti-idiotype antibodies in cancer treatment
Daniel E. Gomez1 , Ana M. Vázquez2, Daniel F. Alonso1 and Amparo Macías2
1 Department of Science and Technology, Universidad Nacional de Quilmes, Buenos Aires, Argentina
2 Centro de Inmunologia Molecular, La Havana, Cuba
*Correspondence: degomez@unq.edu.ar
Edited by:
Wolf Hervé Fridman, INSERM, University Paris Descartes, France
Anti-idiotype antibodies (anti-Id Abs) are antibodies to idiotopes
that are located in the variable region, including the antigen bind-
ing site, of another antibody. When the last is the case, these
anti-Id Abs can act as surrogates of the original antigen. The
capability of anti-Id Abs to modulate the immune response has
been the basis for the development of anti-Id vaccines against
different antigens, including tumor-associated antigens. Over the
years, its use in cancer has been demonstrated as effective and
promising. This book “Anti-idiotype antibodies in cancer treat-
ment” resumes the latest findings in the field. The book starts
with an opinion article by Gomez et al. (2012), whereas the
authors discuss amethod for prioritization of cancer antigens that
paves the way to take more rational, informed decisions in vac-
cine development. Following, we will find a number of reviews
that conform a complete updating on the subject. The first one
by Kieber-Emmons et al. (2012) explore the concept of anti-Id
Abs with its achievements and drawbacks. Following, Ladjemi
(2012) focuses on recent achievements of use of anti-Id Abs as
cancer vaccines in solid tumors. López-Requena et al. (2012)
focus on the role of anti-Id vaccination in cancer management
and on the current developments used to foster anti-idiotypic
B and T cell responses. Vázquez et al. (2012a,b) deeply analyze
the immunological mechanisms involved in the use of these anti-
bodies, while Vázquez et al. (2012a,b) focus on racotumomab,
an anti-Id vaccine already in Phase III clinical trials. Finally,
Fredriksen et al. (2012) present a hypothetical model for how
the APC-targeted vaccine molecules enhance Id-specific T and B
cells. Next, the original article of Segatori et al. (2012) conveys
preclinical research on racotumomab with or without chemother-
apy, and explores the biological role of N-glycolyl gangiosides in
a lung cancer mouse model. Two interesting clinical case studies
are also part of this book. First, Llanos et al. (2012) report a main-
tenance treatment with chemotherapy and immunotherapy in a
patient with non-small cell lung cancer. Also, Sampor et al. (2012)
present results about the immune response to racotumomab in a
child with relapsed neuroblastoma. The book closes with a very
interesting article by Gómez and Ardigo (2012), analyzing the
pharmaceutical perspective of the development of anti-Id Abs in
cancer treatment, with a fresh point of view about the relationship
between academy and industry. We as editors were very happy to
work with such an excellent group of authors, putting together a
book with good quality articles that shed light to the use of anti-
Id Abs in cancer. Likewise, we hope it constitutes to the reader
interesting material for their fields.
REFERENCES
Fredriksen, A. B., Sandlie, I., and
Bogen, B. (2012). Targeted DNA
vaccines for enhanced induction
of idiotype-specific B and T cells.
Front. Oncol. 2:154. doi: 10.3389/
fonc.2012.00154
Gomez, D. E., Vázquez, A. M., and
Alonso, D. F. (2012). Cancer antigen
prioritization: a road map to work
in defining vaccines against spe-
cific targets. A point of view. Front.
Oncol. 2:66. doi: 10.3389/fonc.2012.
00066
Gómez, R. E., and Ardigo, M. L. (2012).
Anti-idiotype antibodies in can-
cer treatment: the pharmaceutical
industry perspective. Front. Oncol.
2:147. doi: 10.3389/fonc.2012.00147
Kieber-Emmons, T., Monzavi-Karbassi,
B., Pashov, A., Saha, S., Murali,
R., and Kohler, H. (2012). The
promise of the anti-idiotype con-
cept. Front. Oncol. 2:196. doi: 10.
3389/fonc.2012.00196
Ladjemi, M. Z. (2012). Anti-idiotypic
antibodies as cancer vaccines:
achievements and future improve-
ments. Front. Oncol. 2:158. doi: 10.
3389/fonc.2012.00158
Llanos, A., Savignano, M., and Cinat,
G. (2012). Maintenance treat-
ment with chemotherapy and
immunotherapy in non-small cell
lung cancer: a case report. Front.
Oncol. 2:152. doi: 10.3389/fonc.
2012.00152
López-Requena, A., Burrone, O. R.,
and Cesco-Gaspere, M. (2012).
Idiotypes as immunogens: facing
the challenge of inducing strong
therapeutic immune responses
against the variable region of
immunoglobulins. Front. Oncol.
2:159. doi: 10.3389/fonc.2012.00159
Sampor, C., Guthmann, M. D.,
Scursoni, A., Cacciavillano, W.,
Torbidoni, A., Galluzzo, L., et al.
(2012). Immune response to raco-
tumomab in a child with relapsed
neuroblastoma. Front. Oncol. 2:195.
doi: 10.3389/fonc.2012.00195
Segatori, V. I., Vazquez, A. M., Gomez,
D. E., Gabri, M. R., and Alonso,
D. F. (2012). Preclinical evaluation
of racotumomab, an anti-idiotype
monoclonal antibody to N-glycolyl-
containing gangliosides, with or
without chemotherapy in a mouse
model of non-small cell lung cancer.
Front. Oncol. 2:160. doi: 10.3389/
fonc.2012.00160
Vázquez, A. M., Hernández, A.
M., Macías, A., Montero, E.,
Gómez, D. E., Alonso, D. F.,
et al. (2012a). Racotumomab: an
anti-idiotype vaccine related to
N-glycolyl-containing gangliosides
– preclinical and clinical data. Front.
Oncol. 2:150. doi: 10.3389/fonc.
2012.00150
Vázquez, A. M. H., Rodríguez-
Zhurbenko, N., and López, A.
M. V. (2012b). Anti-ganglioside
anti-idiotypic vaccination: more
than molecular mimicry. Front.
Oncol. 2:170. doi: 10.3389/fonc.
2012.00170
Received: 01 February 2013; accepted:
11 February 2013; published online: 26
February 2013.
Citation: Gomez DE, Vázquez AM,
Alonso DF and Macías A (2013) Anti-
idiotype antibodies in cancer treatment.
Front. Oncol. 3:37. doi: 10.3389/fonc.
2013.00037
This article was submitted to Frontiers in
Tumor Immunity, a specialty of Frontiers
in Oncology.
Copyright © 2013 Gomez, Vázquez,
Alonso and Macías. This is an open-
access article distributed under the terms
of the Creative Commons Attribution
License, which permits use, distribution
and reproduction in other forums, pro-
vided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
www.frontiersin.org February 2013 | Volume 3 | Article 37 | 1
*


Crossref

LAReferencia - Red Federada de Repositorios Institucionales de Publicaciones Científicas Latinoamericanas

EDITORIALpublished: 26 February 2013doi: 10.3389/fonc.2013.00037Anti-idiotype antibodies in cancer treatmentDaniel E. Gomez1 , Ana M. Vázquez2, Daniel F. Alonso1 and Amparo Macías21 Department of Science and Technology, Universidad Nacional de Quilmes, Buenos Aires, Argentina2 Centro de Inmunologia Molecular, La Havana, Cuba*Correspondence: degomez@unq.edu.arEdited by:Wolf Hervé Fridman, INSERM, University Paris Descartes, FranceAnti-idiotype antibodies (anti-Id Abs) are antibodies to idiotopesthat are located in the variable region, including the antigen bind-ing site, of another antibody. When the last is the case, theseanti-Id Abs can act as surrogates of the original antigen. Thecapability of anti-Id Abs to modulate the immune response hasbeen the basis for the development of anti-Id vaccines againstdifferent antigens, including tumor-associated antigens. Over theyears, its use in cancer has been demonstrated as effective andpromising. This book “Anti-idiotype antibodies in cancer treat-ment” resumes the latest findings in the field. The book startswith an opinion article by Gomez et al. (2012), whereas theauthors discuss a method for prioritization of cancer antigens thatpaves the way to take more rational, informed decisions in vac-cine development. Following, we will find a number of reviewsthat conform a complete updating on the subject. The first oneby Kieber-Emmons et al. (2012) explore the concept of anti-IdAbs with its achievements and drawbacks. Following, Ladjemi(2012) focuses on recent achievements of use of anti-Id Abs ascancer vaccines in solid tumors. López-Requena et al. (2012)focus on the role of anti-Id vaccination in cancer managementand on the current developments used to foster anti-idiotypicB and T cell responses. Vázquez et al. (2012a,b) deeply analyzethe immunological mechanisms involved in the use of these anti-bodies, while Vázquez et al. (2012a,b) focus on racotumomab,an anti-Id vaccine already in Phase III clinical trials. Finally,Fredriksen et al. (2012) present a hypothetical model for howthe APC-targeted vaccine molecules enhance Id-specific T and Bcells. Next, the original article of Segatori et al. (2012) conveyspreclinical research on racotumomab with or without chemother-apy, and explores the biological role of N-glycolyl gangiosides ina lung cancer mouse model. Two interesting clinical case studiesare also part of this book. First, Llanos et al. (2012) report a main-tenance treatment with chemotherapy and immunotherapy in apatient with non-small cell lung cancer. Also, Sampor et al. (2012)present results about the immune response to racotumomab in achild with relapsed neuroblastoma. The book closes with a veryinteresting article by Gómez and Ardigo (2012), analyzing thepharmaceutical perspective of the development of anti-Id Abs incancer treatment, with a fresh point of view about the relationshipbetween academy and industry. We as editors were very happy towork with such an excellent group of authors, putting together abook with good quality articles that shed light to the use of anti-Id Abs in cancer. Likewise, we hope it constitutes to the readerinteresting material for their fields.REFERENCESFredriksen, A. B., Sandlie, I., andBogen, B. (2012). Targeted DNAvaccines for enhanced inductionof idiotype-specific B and T cells.Front. Oncol. 2:154. doi: 10.3389/fonc.2012.00154Gomez, D. E., Vázquez, A. M., andAlonso, D. F. (2012). Cancer antigenprioritization: a road map to workin defining vaccines against spe-cific targets. A point of view. Front.Oncol. 2:66. doi: 10.3389/fonc.2012.00066Gómez, R. E., and Ardigo, M. L. (2012).Anti-idiotype antibodies in can-cer treatment: the pharmaceuticalindustry perspective. Front. Oncol.2:147. doi: 10.3389/fonc.2012.00147Kieber-Emmons, T., Monzavi-Karbassi,B., Pashov, A., Saha, S., Murali,R., and Kohler, H. (2012). Thepromise of the anti-idiotype con-cept. Front. Oncol. 2:196. doi: 10.3389/fonc.2012.00196Ladjemi, M. Z. (2012). Anti-idiotypicantibodies as cancer vaccines:achievements and future improve-ments. Front. Oncol. 2:158. doi: 10.3389/fonc.2012.00158Llanos, A., Savignano, M., and Cinat,G. (2012). Maintenance treat-ment with chemotherapy andimmunotherapy in non-small celllung cancer: a case report. Front.Oncol. 2:152. doi: 10.3389/fonc.2012.00152López-Requena, A., Burrone, O. R.,and Cesco-Gaspere, M. (2012).Idiotypes as immunogens: facingthe challenge of inducing strongtherapeutic immune responsesagainst the variable region ofimmunoglobulins. Front. Oncol.2:159. doi: 10.3389/fonc.2012.00159Sampor, C., Guthmann, M. D.,Scursoni, A., Cacciavillano, W.,Torbidoni, A., Galluzzo, L., et al.(2012). Immune response to raco-tumomab in a child with relapsedneuroblastoma. Front. Oncol. 2:195.doi: 10.3389/fonc.2012.00195Segatori, V. I., Vazquez, A. M., Gomez,D. E., Gabri, M. R., and Alonso,D. F. (2012). Preclinical evaluationof racotumomab, an anti-idiotypemonoclonal antibody to N-glycolyl-containing gangliosides, with orwithout chemotherapy in a mousemodel of non-small cell lung cancer.Front. Oncol. 2:160. doi: 10.3389/fonc.2012.00160Vázquez, A. M., Hernández, A.M., Macías, A., Montero, E.,Gómez, D. E., Alonso, D. F.,et al. (2012a). Racotumomab: ananti-idiotype vaccine related toN-glycolyl-containing gangliosides– preclinical and clinical data. Front.Oncol. 2:150. doi: 10.3389/fonc.2012.00150Vázquez, A. M. H., Rodríguez-Zhurbenko, N., and López, A.M. V. (2012b). Anti-gangliosideanti-idiotypic vaccination: morethan molecular mimicry. Front.Oncol. 2:170. doi: 10.3389/fonc.2012.00170Received: 01 February 2013; accepted:11 February 2013; published online: 26February 2013.Citation: Gomez DE, Vázquez AM,Alonso DF and Macías A (2013) Anti-idiotype antibodies in cancer treatment.Front. Oncol. 3:37. doi: 10.3389/fonc.2013.00037This article was submitted to Frontiers inTumor Immunity, a specialty of Frontiersin Oncology.Copyright © 2013 Gomez, Vázquez,Alonso and Macías. This is an open-access article distributed under the termsof the Creative Commons AttributionLicense, which permits use, distributionand reproduction in other forums, pro-vided the original authors and sourceare credited and subject to any copy-right notices concerning any third-partygraphics etc.www.frontiersin.org February 2013 | Volume 3 | Article 37 | 1*

English

http://ri.conicet.gov.ar/bitstream/handle/11336/3241/CONICET_Digital_Nro.4405_A.pdf?sequence=2&isAllowed=y

Anti-idiotype antibodies in cancer treatment

Abstract

Similar works

Full text

Available Versions

CONICET Digital

Directory of Open Access Journals

Frontiers - Publisher Connector

Frontiers - Publisher Connector

Crossref

LAReferencia - Red Federada de Repositorios Institucionales de Publicaciones Científicas Latinoamericanas